查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918116

难治性忧郁症市场－2026-2031年预测

Treatment-Resistant Depression Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2025 年，难治性忧郁症治疗市场规模将达到 37.94 亿美元，到 2031 年将达到 53.42 亿美元，复合年增长率为 5.87%。

预计在预测期内，难治性忧郁症（TRD）治疗市场将稳定成长，其主要驱动因素是相当一部分重度忧郁症（MDD）患者对第一线和第二线抗忧郁症治疗持续无效。 TRD通常定义为至少两次足量抗忧郁症单药治疗无效，影响全球约2.8亿忧郁症成年患者的30%，并与更高的自杀风险、功能障碍和医疗资源利用率相关。

忧郁症及其难治性形式的全球负担日益加重，是推动这一成长要素的核心因素，而与忧郁症直接相关的自杀率上升更是雪上加霜。忧郁症仍然是导致残疾的主要原因之一，世界卫生组织的数据显示，每年约有70万人死于自杀。未经治疗或控制不佳的忧郁症与自杀之间存在密切关联，凸显了有效难治性忧郁症干预措施的临床紧迫性。

在持续的国际和国家宣传活动的支持下，意识提升，正促使人们更积极主动地寻求帮助，并及早识别无反应者。世界卫生组织主导的持续努力、欧洲精神卫生行动计划的成果、世界精神卫生日宣传活动以及各国项目，正帮助精神卫生保健正常化，减少歧视，使更多患者能够进入专科机构接受难治性抑郁症的诊断和治疗。

治疗创新主要集中于具有新型作用机制的速效药物，以克服传统单胺抗忧郁症的限制。滴鼻剂esketamine（S-氯胺酮）是目前唯一获得FDA核准的、专门用于治疗难治性抑郁症（TRD）的治疗方法，其真实世界数据表明，该药物能够快速且持续地缓解症状，从而不断推动治疗领域的拓展。在传统疗法中，第二代抗精神病药物和锂盐辅助疗法拥有最可靠的实证医学证据，而具有麸胺酸调节特性的候选药物也持续推进临床开发平臺。

北美地区报告的难治性忧郁症盛行率最高，并凭藉先进的研究基础设施、快速的监管审批流程以及对药物和介入疗法（例如，经颅磁刺激、电休克疗法以及根据风险评估和缓解策略（REMS）使用的艾司esketamine）的有利报销政策，保持着明显的市场优势。该地区受益于大量的製药投资和成熟的学术性情绪障碍中心网络，这些中心能够提供复杂的多步骤治疗流程。

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 难治性忧郁症治疗市场（依类型划分）

  • 介绍
  • 温和的
  • 严重

6. 难治性忧郁症药物市场

  • 介绍
  • NMDA
  • 抗忧郁症
  • 抗精神病药物
  • 其他的

7. 依给药途径分類的难治性忧郁症治疗市场

  • 介绍
  • 口服
  • 肠外
  • 其他的

8. 难治性忧郁症治疗市场（依通路划分）

  • 介绍
  • 在线的
  • 离线
    • 医院药房
    • 药局

9. 各地区难治性忧郁症治疗市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十二章：公司简介

  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • AbbVie Inc
  • Otsuka Pharmaceutical Co., Ltd
  • Eli Lilly and Company
  • AstraZeneca Plc
  • Sage Therapeutics

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615588

The Treatment-Resistant Depression Treatment Market is projected to expand at a 5.87% CAGR, attaining USD 5.342 billion in 2031 from USD 3.794 billion in 2025.

The treatment-resistant depression (TRD) treatment market is projected to expand at a steady pace throughout the forecast period, driven by the persistent failure of first- and second-line antidepressant therapies in a substantial subset of patients with major depressive disorder (MDD). TRD, typically defined as non-response to at least two adequate trials of antidepressant monotherapy, affects approximately 30% of the 280 million adults worldwide with depression and is associated with markedly elevated suicide risk, functional impairment, and healthcare utilization.

Core growth drivers remain the escalating global burden of MDD and its treatment-refractory forms, compounded by heightened suicide rates directly linked to depressive illness. Depression continues to rank among the leading causes of disability, with suicide claiming approximately 700,000 lives annually according to WHO data. The strong correlation between untreated or inadequately managed depression and completed suicide underscores the clinical urgency for effective TRD interventions.

Increased public and professional awareness, supported by sustained international and national campaigns, is translating into higher help-seeking behavior and earlier identification of non-responders. Ongoing WHO-led initiatives, the legacy of the European Mental Health Action Plan, World Mental Health Day mobilization, and national programs continue to normalize mental health care and reduce stigma, funneling greater patient volumes into specialist settings where TRD is diagnosed and managed.

Therapeutic innovation is centered on rapid-acting and mechanistically novel agents that address the limitations of conventional monoaminergic antidepressants. Esketamine (S-ketamine) nasal spray remains the only FDA-approved therapy specifically indicated for TRD and continues to drive category expansion through real-world evidence of rapid and sustained symptom reduction. Augmentation strategies employing second-generation antipsychotics and lithium retain the strongest evidence base among traditional approaches, while glutamate-modulating candidates continue to advance through clinical pipelines.

North America maintains clear market dominance, supported by the highest reported TRD prevalence, advanced research infrastructure, rapid regulatory review pathways, and favorable reimbursement for both pharmacotherapy and interventional modalities (e.g., TMS, ECT, and esketamine administration under REMS). The region benefits from concentrated pharmaceutical investment and a mature network of academic mood-disorder centers capable of delivering complex, multistep treatment algorithms.

Key industry participants are pursuing differentiated mechanisms of action to capture share in this high-unmet-need segment:

  • Pfizer Inc continues to support PRISTIQ (desvenlafaxine) for MDD while maintaining broader neuroscience capabilities that indirectly bolster TRD management.
  • Novartis AG is advancing MIJ-821, a direct NMDA receptor antagonist, currently in phase II evaluation for TRD, representing a next-generation effort to replicate and potentially improve upon the esketamine proof-of-concept.
  • Hikma Pharmaceuticals Plc contributes through its expanding portfolio of generic and specialty injectables that support acute stabilization and augmentation protocols.

The competitive landscape remains dynamic, with established players focusing on life-cycle management of approved assets and emerging biotechnology firms pursuing novel glutamatergic, opioid-modulating, and neuroplasticity-enhancing mechanisms. Increasing venture funding directed toward mental health platforms continues to fuel early-stage research, although post-2023 capital deployment patterns reflect a more selective investment climate.

Overall, the TRD treatment sector is positioned for sustained growth, underpinned by immutable epidemiological trends, progressive destigmatization, and a broadening armamentarium led by esketamine and next-wave NMDA-targeted therapies. North America will continue to lead in market size and innovation velocity, while regulatory approvals and guideline inclusion of rapid-acting agents progressively reshape standard-of-care algorithms for the estimated one-third of MDD patients who fail conventional antidepressant treatment.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Global Treatment-Resistant Depression Treatment Market is analyzed into the following segments:

  • By Type
  • Mild
  • Severe
  • By Drug Type
  • NMDA
  • Antidepressants
  • Antipsychotics
  • Others
  • By Route of Administration
  • Oral
  • Parenteral
  • Others
  • By Distribution Channel
  • Online
  • Offline
  • Hospital Pharmacies
  • Drug Stores
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations
  • 3.8. Products in Pipeline

4. TECHNOLOGICAL OUTLOOK

5. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Mild
  • 5.3. Severe

6. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. NMDA
  • 6.3. Antidepressants
  • 6.4. Antipsychotics
  • 6.5. Others

7. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental
  • 7.4. Others

8. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Online
  • 8.3. Offline
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores

9. TREATMENT-DEPRESSION RESISTANT TREATMENT MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Pfizer Inc
  • 11.2. Novartis AG
  • 11.3. Johnson & Johnson
  • 11.4. AbbVie Inc
  • 11.5. Otsuka Pharmaceutical Co., Ltd
  • 11.6. Eli Lilly and Company
  • 11.7. AstraZeneca Plc
  • 11.8. Sage Therapeutics

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations